Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.30% | 21.38% | -1.07% | 21.77% | 10.17% |
| Total Depreciation and Amortization | -63.16% | -94.90% | -94.27% | -85.26% | -88.13% |
| Total Amortization of Deferred Charges | 30.03% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.78% | -17.04% | -26.97% | -40.72% | -33.34% |
| Change in Net Operating Assets | 46.19% | -45.71% | 336.65% | -84.77% | 15.82% |
| Cash from Operations | 24.57% | 21.94% | 4.74% | -39.27% | 6.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 143.10% | -67.36% | 42.62% |
| Cash from Investing | -100.00% | -99.84% | 143.16% | -67.31% | 43.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16,400.00% | -- | 29.46% | -100.00% | -97.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.67% | -- | 277.37% | -108.88% | 595.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -751.77% | -131.93% | 140.02% | -96.36% | 88.99% |